FDA “Fast-Tracks” Farxiga for Heart Failure Benefits

Research has shown that diabetes drugs in the SGLT2 inhibitor class can have cardiovascular benefits. Now the FDA has given a Fast Track Designation to accelerate study of how one of these drugs, Farxiga (dapagliflozin) may help reduce death and heart failure after a heart attack. Read more

Posted in Drugs